[go: up one dir, main page]

AR094374A1 - Composiciones y métodos para el tratamiento de trastornos metabólicos - Google Patents

Composiciones y métodos para el tratamiento de trastornos metabólicos

Info

Publication number
AR094374A1
AR094374A1 ARP140100044A ARP140100044A AR094374A1 AR 094374 A1 AR094374 A1 AR 094374A1 AR P140100044 A ARP140100044 A AR P140100044A AR P140100044 A ARP140100044 A AR P140100044A AR 094374 A1 AR094374 A1 AR 094374A1
Authority
AR
Argentina
Prior art keywords
biguanide
release
biguanide compound
compounds
compositions
Prior art date
Application number
ARP140100044A
Other languages
English (en)
Inventor
D Baron Alain
S Fineman Mark
Kim Terru
Kwaku Dordunoo Stephen
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR094374(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Publication of AR094374A1 publication Critical patent/AR094374A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composiciones y métodos para mejorar la farmacocinética y reducir el riesgo de eventos adversos resultantes de la administración de compuestos de biguanida, que comprenden administrar formulaciones de acción retardada de dichos compuestos cuya liberación incluye una fase de latencia. Reivindicación 1: Una composición farmacéutica de liberación demorada apropiada para administrar compuestos de biguanida, caracterizada porque comprende una forma de dosificación oral que tiene un núcleo que comprende una cantidad eficaz para el uso terapéutico de un compuesto de biguanida y un recubrimiento entérico que rodea el núcleo, que es útil para demorar la liberación del compuesto de biguanida después de la ingestión, una vez alcanzada la porción distal del intestino delgado, y para minimizar la liberación del compuesto de biguanida de la forma de dosificación oral, con una fase de demora de al menos aproximadamente diez minutos, después de tomar contacto con un pH de al menos aproximadamente 6,0. Reivindicación 18: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque el compuesto de biguanida se selecciona del grupo que consiste en la metformina, la fenformina, la buformina y la imeglimina.
ARP140100044A 2013-01-05 2014-01-06 Composiciones y métodos para el tratamiento de trastornos metabólicos AR094374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361749307P 2013-01-05 2013-01-05

Publications (1)

Publication Number Publication Date
AR094374A1 true AR094374A1 (es) 2015-07-29

Family

ID=50030486

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100044A AR094374A1 (es) 2013-01-05 2014-01-06 Composiciones y métodos para el tratamiento de trastornos metabólicos

Country Status (19)

Country Link
US (3) US20140193498A1 (es)
EP (2) EP2941245B1 (es)
JP (1) JP6333855B2 (es)
KR (1) KR102229492B1 (es)
CN (2) CN105101956B (es)
AR (1) AR094374A1 (es)
AU (1) AU2014203942B2 (es)
CA (1) CA2896864C (es)
CL (1) CL2015001914A1 (es)
CU (1) CU20150071A7 (es)
EA (1) EA039530B1 (es)
HK (1) HK1214966A1 (es)
IL (1) IL239722B (es)
MX (2) MX2015008625A (es)
NZ (1) NZ709525A (es)
PH (1) PH12015501520A1 (es)
SG (2) SG10201705437SA (es)
WO (1) WO2014107617A1 (es)
ZA (1) ZA201504858B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
SG10201607085WA (en) 2011-01-07 2016-10-28 Elcelyx Therapeutics Inc Chemosensory Receptor Ligand-Based Therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
EP2800562A2 (en) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
EP2800561B1 (en) 2012-01-06 2020-08-19 Anji Pharma (US) LLC Biguanide compositions and methods of treating metabolic disorders
EP3236943B1 (en) * 2014-12-24 2023-01-25 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2016205754A1 (en) * 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
US20190382462A1 (en) * 2017-01-13 2019-12-19 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
CN114072138A (zh) * 2019-06-03 2022-02-18 R.P.谢勒技术有限公司 延迟释放软凝胶胶囊
WO2023278300A1 (en) * 2021-06-28 2023-01-05 ImmunoMet Therapeutics, Inc. Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1209253A (en) 1913-01-09 1916-12-19 Automatic Electric Co Impulse-transmitting device.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
IL131659A (en) 1997-04-15 2005-07-25 Csir Pharmaceutical compositions having appetite suppressant activity
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
MXPA03006217A (es) * 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
US7998947B2 (en) 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
EP1549296A4 (en) * 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co METFORMIN FORMULATIONS WITH DELAYED RELEASE
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
US7919236B2 (en) 2002-12-18 2011-04-05 Givaudan Sa G-proteins
DE10308504A1 (de) 2003-02-26 2004-09-09 Basf Ag Enzymatische Herstellung von (Meth)acrylsäureestern
US20060172020A1 (en) 2003-07-17 2006-08-03 Djang Arthur H Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabeties
US8158372B2 (en) 2004-04-20 2012-04-17 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Agonists of a bitter taste receptor and uses thereof
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
US7829299B2 (en) 2004-11-18 2010-11-09 Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts Agonists of bitter taste receptors and uses thereof
US20060222709A1 (en) 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
RU2007144076A (ru) 2005-04-28 2009-06-10 Адзиномото Ко., Инк. (Jp) Новое производное лактама
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
JP2009501317A (ja) 2005-06-22 2009-01-15 セノミクス・インコーポレーテッド コーヒー中の苦味分子（クロロゲン酸ラクトン）により活性化されるヒトｔ２ｒ受容体の同定、およびヒト苦味味覚モジュレーターを同定するための関連するアッセイ
BRPI0615410A2 (pt) * 2005-08-30 2013-02-13 Nicholas Piramal India Ltd composiÇço farmacÊutica de liberaÇço prolongada de metformina e processo para produÇço da mesma
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (ja) 2006-01-11 2007-08-23 Canon Inc 情報処理装置及びその制御方法、プログラム、記憶媒体
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (zh) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 一种促进肠胃蠕动的药物组合物
CA2660464A1 (en) 2006-08-17 2008-02-21 Unilever Plc Processes for production of hoodia plant extracts containing steroidal glycosides
MX2009001866A (es) 2006-08-24 2009-03-02 Unilever Nv Proceso para la preparacion de una composicion que comprende glucosidos esteroides.
CN101522702A (zh) 2006-09-05 2009-09-02 塞诺米克斯公司 人T2R受体hT2R50的新单体型及其在鉴定人苦味调节剂的测定法中的用途
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
US20100316736A1 (en) 2007-10-24 2010-12-16 Desert Labs Agriculture Cooperative Association Ltd. Appetite suppressant
WO2009095993A1 (ja) 2008-01-29 2009-08-06 Nakamori Pharmaceutical Co., Ltd. 医薬組成物
US9844224B2 (en) 2008-05-23 2017-12-19 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
US8546085B2 (en) 2008-06-13 2013-10-01 Givaudan Sa Methods of identifying modulators of the bitter taste receptor TAS2R44
WO2010022529A1 (en) 2008-08-29 2010-03-04 Givaudan Sa Methods to identify modulators
ES2550077T3 (es) 2008-08-29 2015-11-04 Suntory Holdings Limited Nuevo tetrámero de galato de epigalocatequina y mejorador de la función del endotelio vascular que comprende el mismo
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
CN102272129B (zh) 2009-01-03 2014-10-08 静冈县公立大学法人 硫酸化c-糖苷及其分离方法以及合成方法
US8709745B2 (en) 2009-07-28 2014-04-29 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Methods for isolating ligands of the human bitter taste receptor TAS2R49
ES2437921T3 (es) 2009-10-21 2014-01-15 Wisconsin Alumni Research Foundation Método para prevenir la diabetes tipo 1
CN102762259A (zh) 2009-12-04 2012-10-31 高露洁-棕榄公司 含有倒捻子提取物的口腔组合物及相关方法
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
CN101978956B (zh) * 2010-10-13 2012-03-28 北京京丰制药有限公司 盐酸二甲双胍肠溶片及其制备方法
SG10201607085WA (en) * 2011-01-07 2016-10-28 Elcelyx Therapeutics Inc Chemosensory Receptor Ligand-Based Therapies
EP2800562A2 (en) * 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂

Also Published As

Publication number Publication date
BR112015016111A2 (pt) 2020-01-28
IL239722A0 (en) 2015-08-31
EA039530B1 (ru) 2022-02-08
NZ709525A (en) 2020-07-31
SG11201505240QA (en) 2015-08-28
JP2016504384A (ja) 2016-02-12
CA2896864A1 (en) 2014-07-10
SG10201705437SA (en) 2017-07-28
US20250000804A1 (en) 2025-01-02
US20200093750A1 (en) 2020-03-26
EP4410380A2 (en) 2024-08-07
MX2020011594A (es) 2022-01-13
PH12015501520A1 (en) 2015-09-21
JP6333855B2 (ja) 2018-05-30
EP2941245B1 (en) 2024-06-26
EP4410380A3 (en) 2024-10-23
AU2014203942B2 (en) 2019-01-03
HK1214966A1 (zh) 2016-08-12
CA2896864C (en) 2021-04-20
KR102229492B1 (ko) 2021-03-17
CN105101956A (zh) 2015-11-25
CN110051638A (zh) 2019-07-26
CU20150071A7 (es) 2016-01-29
AU2014203942A1 (en) 2015-07-16
US20140193498A1 (en) 2014-07-10
MX2015008625A (es) 2015-09-23
EA201591085A1 (ru) 2015-12-30
KR20150103079A (ko) 2015-09-09
ZA201504858B (en) 2018-12-19
CN110051638B (zh) 2022-02-01
CN105101956B (zh) 2018-12-07
CL2015001914A1 (es) 2015-09-04
IL239722B (en) 2022-04-01
EP2941245A1 (en) 2015-11-11
WO2014107617A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
AR091089A1 (es) Metodos de tratamiento que utilizan un compuesto de biguanida en una formulacion de liberacion demorada
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
CO2019008053A2 (es) Agente terapéutico para enfermedades del hígado
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
WO2015099838A3 (en) Compositions and methods of treating ocular diseases
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
BR112015019264A8 (pt) cápsulas para o tratamento de helicobacter pylori e seu uso".
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
WO2012106058A3 (en) Animal treatments
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
DOP2013000115A (es) Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MX2013008992A (es) Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
JP2017530142A5 (es)
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
RU2014146303A (ru) Способ лечения угрей
RU2013126798A (ru) Комбинированная терапия дексаметазоном
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

Legal Events

Date Code Title Description
FC Refusal